Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Accounts Payables (2016 - 2025)

Historic Accounts Payables for RedHill Biopharma (RDHL) over the last 15 years, with Q2 2025 value amounting to $835000.0.

  • RedHill Biopharma's Accounts Payables fell 5632.85% to $835000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $835000.0, marking a year-over-year decrease of 5632.85%. This contributed to the annual value of $1.2 million for FY2024, which is 6436.85% down from last year.
  • RedHill Biopharma's Accounts Payables amounted to $835000.0 in Q2 2025, which was down 5632.85% from $1.2 million recorded in Q4 2024.
  • RedHill Biopharma's Accounts Payables' 5-year high stood at $15.2 million during Q3 2021, with a 5-year trough of $835000.0 in Q2 2025.
  • Over the past 5 years, RedHill Biopharma's median Accounts Payables value was $4.4 million (recorded in 2022), while the average stood at $5.8 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first soared by 15067.82% in 2021, then tumbled by 6861.92% in 2022.
  • Over the past 5 years, RedHill Biopharma's Accounts Payables (Quarter) stood at $11.7 million in 2021, then crashed by 63.73% to $4.2 million in 2022, then fell by 22.51% to $3.3 million in 2023, then plummeted by 64.37% to $1.2 million in 2024, then decreased by 28.51% to $835000.0 in 2025.
  • Its last three reported values are $835000.0 in Q2 2025, $1.2 million for Q4 2024, and $1.9 million during Q2 2024.